Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Sees Large Increase in Short Interest

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) saw a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 22,800 shares, an increase of 31.0% from the November 15th total of 17,400 shares. Approximately 1.4% of the shares of the company are short sold. Based on an average daily trading volume, of 2,580,000 shares, the short-interest ratio is presently 0.0 days.

Analyst Ratings Changes

Separately, StockNews.com began coverage on Galmed Pharmaceuticals in a report on Wednesday, October 9th. They issued a “sell” rating on the stock.

Galmed Pharmaceuticals Stock Up 5.5 %

Galmed Pharmaceuticals stock traded up $0.16 during mid-day trading on Friday, hitting $2.97. 31,667 shares of the company’s stock traded hands, compared to its average volume of 714,124. The firm has a 50 day moving average price of $3.32 and a 200 day moving average price of $3.96. The company has a market cap of $1.90 million, a PE ratio of -0.18 and a beta of 0.75. Galmed Pharmaceuticals has a one year low of $2.56 and a one year high of $23.80.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.